Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients

An experimental treatment for HIV developed by GlaxoSmithKline Plc, Pfizer Inc. and Shionogi & Co. reduced the virus in hard-to-treat patients in a late-stage study, providing further support for a regulatory filing by the end of this year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.